PPD

Medical monitoring is a vital part of every pediatric clinical trial. Our primary goal is to safeguard the health and interests of all participating children, considering their unique ages and developmental stages. Anu Ohrling, MD MBA delves into how our skilled team of pediatricians employs a comprehensive and multidisciplinary approach to help ensure the safety and well-being of every child participating in a #clinicaltrial. » https://bit.ly/44vKXEd

🗳️ Last week to vote! » https://bit.ly/46V4v5I We're honored to be considered for the Society for Clinical Research Sites (SCRS) Eagle Award, which recognizes outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships. We're grateful for the collaborative relationships with our site partners, and if you feel we have met these exceptional standards, we would be humbled to receive your vote for best CRO.

Looking to scale up your #cellandgenetherapy #clinicaltrial? We have the therapeutic expertise to elevate your research to new heights. We bring extensive experience in efficiently managing large-scale trials, optimizing processes and ensuring regulatory compliance every step of the way. Our expertise in logistics, data management and patient recruitment streamlines operations, enabling seamless expansion while maintaining quality and safety standards. Learn more about how we can support your cell and gene therapy research. » https://bit.ly/3V8YOOd

“Early on, [focus on] understanding what’s important to patients and their families so that they stay engaged with the trial, what’s important to the sites in terms of how to arrange the day to be less burdensome, and then how to really understand what’s clinically meaningful to the patients and their parents from a protocol perspective.” In the latest episode of ACRO’s Good Clinical Podcast, Susan McCune, MD, VP, Pediatrics & Clinical Pharmacology, PPD and Jacqui Whiteway, Senior Director & Pediatric Strategy Liaison, Center for Pediatric Clinical Development, ICON plc, discuss what makes pediatric clinical trials unique and how industry can make participation easier for pediatric patients and their families. Listen to the full episode: https://lnkd.in/gdMz_agR

Seeking to develop #neurodegenerative disorder treatments? Partner with our experienced #clinicalresearch team, equipped with operational and medical expertise across multiple indications, to explore novel approaches like #decentralizedtrials and clinical trial simulations. » https://bit.ly/3xyIXOQ

"This new building was purpose-built with our specific lab needs in mind, and the work performed here in Middleton will continue to have a major impact on the future of clinical research and development." We recently cut the ribbon on a new facility at our GMP laboratory in Middleton, Wisconsin, an expansion that enhances our analytical capabilities through high quality scientific expertise and industry-leading technologies to help our customers bring safe, effective medicines to patients. 📰 » https://bit.ly/4fnW1IH

Working with an end-to-end, integrated CRO and CDMO partner provides sponsors with a wide range of innovative capabilities. Our integrated solutions can help accelerate innovation through integrated timelines, joint project management and streamlined information sharing, expedited communication within the integrated structure, proactive risk mitigation and swift adaptation of strategies, and faster decision-making capabilities through visibility of key project milestones. Learn more about our solutions. » https://bit.ly/3XBmdc8 #drugdevelopment #biopharmaceuticals #clinicalresearch

We’re looking forward to #AAIC24 and coming together with the global research community to share and discuss the latest progress in understanding, diagnosing, treating and preventing #AlzheimersDisease and related #dementias. Meet our team at booth 920, and join our poster presentation with Stephen J. Peroutka, M.D., Ph.D examining comorbidity profiles of younger vs. older individuals with or without Alzheimer’s. Learn more or pre-book a meeting with us. » https://bit.ly/3y0K3DP

There are no U.S. FDA-approved treatments for 95% of rare disorders, creating an immeasurable physical and mental toll on patients and their families. In all of our work, with both adult and pediatric patients, we recognize the person behind the condition — a focal point in our study designs. Find out more about our work in #rarediseases and methods of overcoming obstacles. » https://bit.ly/3Iexkif

With a vast array of services spanning the entire #drugdevelopment life cycle, we offer site- and patient-centric solutions for innovative #oncology programs. Learn more about these specialized capabilities. » https://bit.ly/3WofqSu